↓ Skip to main content

Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

Overview of attention for article published in New England Journal of Medicine, June 2005
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
39 news outlets
policy
4 policy sources
patent
36 patents

Citations

dimensions_citation
1365 Dimensions

Readers on

mendeley
270 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
Published in
New England Journal of Medicine, June 2005
DOI 10.1056/nejmoa043470
Pubmed ID
Authors

George K.K. Lau, Teerha Piratvisuth, Kang Xian Luo, Patrick Marcellin, Satawat Thongsawat, Graham Cooksley, Edward Gane, Michael W. Fried, Wan Cheng Chow, Seung Woon Paik, Wen Yu Chang, Thomas Berg, Robert Flisiak, Philip McCloud, Nigel Pluck

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 270 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 <1%
Netherlands 1 <1%
Korea, Republic of 1 <1%
India 1 <1%
Colombia 1 <1%
Argentina 1 <1%
United Kingdom 1 <1%
China 1 <1%
Belgium 1 <1%
Other 0 0%
Unknown 260 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 52 19%
Student > Ph. D. Student 36 13%
Student > Bachelor 26 10%
Other 21 8%
Student > Master 20 7%
Other 59 22%
Unknown 56 21%
Readers by discipline Count As %
Medicine and Dentistry 117 43%
Agricultural and Biological Sciences 32 12%
Biochemistry, Genetics and Molecular Biology 18 7%
Immunology and Microbiology 10 4%
Pharmacology, Toxicology and Pharmaceutical Science 7 3%
Other 19 7%
Unknown 67 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 294. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 June 2023.
All research outputs
#108,228
of 23,946,786 outputs
Outputs from New England Journal of Medicine
#2,688
of 31,563 outputs
Outputs of similar age
#103
of 57,594 outputs
Outputs of similar age from New England Journal of Medicine
#2
of 160 outputs
Altmetric has tracked 23,946,786 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 31,563 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 121.2. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 57,594 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 160 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.